Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jun 07, 2022 9:27pm
204 Views
Post# 34738931

RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff
I agree with you aobut the exclusivity but the problem I am having is that the company needs to have product approval before the patents expire and Matt even suggested as much at the recent presentation. So that is my worry if anything is delayed or the trial takes longer than expected, that would bring us very close to the expiration of the composition of matter patent but at this time we do not know when all of the other patents start to expire and as I mentioned, onc lost 60 patents in just the last quarter which I do not take as a good sign of the patent portfolio. That is why I am hoping that a deal can be done sooner than later and really think that a buyout would be the best protection for the company in the long run
<< Previous
Bullboard Posts
Next >>